Treatment of blepharitis: Recent clinical trials

Ocular Surface

Volumn 12, Issue 4, 2014, Pages 273-284

  Pflugfelder, Stephen C ^a   Karpecki, Paul M ^b   Perez, Victor L ^c  

^a CULLEN EYE INSTITUTE   (United States)

^b Kentucky Center for Vision   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotics; Bacteria; Blepharitis; Corticosteroids; Cyclosporine; Inflammation; Meibomian gland dysfunction

Indexed keywords

ANTIBIOTIC AGENT; ARTIFICIAL TEAR; AZITHROMYCIN; BESIFLOXACIN; CARBOXYMETHYLCELLULOSE; CORTICOSTEROID; CYCLOSPORIN; DEXAMETHASONE; DOXYCYCLINE; ERYTHROMYCIN; ESSENTIAL FATTY ACID; GAMMA LINOLENIC ACID; LINOLEIC ACID; MACROLIDE; MINOCYCLINE; QUINOLONE DERIVATIVE; TETRACYCLINE; TOBRAMYCIN; TRIMETHOPRIM;

ARTICLE; BACTERIAL CLEARANCE; BLEPHARITIS; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; DEMODICOSIS; DIET SUPPLEMENTATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; ENVIRONMENTAL FACTOR; EYELASH; GASTROINTESTINAL SYMPTOM; HUMAN; HYGIENE; INCIDENCE; MEIBOMIAN GLAND DYSFUNCTION; MITE; MOLECULAR INTERACTION; PHASE TRANSITION; PHOTOSENSITIZATION; PRACTICE GUIDELINE; PREVALENCE; STREPTOCOCCUS PNEUMONIA; TREATMENT DURATION; VAGINITIS; VISUAL ACUITY; DISEASE MANAGEMENT; PROCEDURES;

BLEPHARITIS; CLINICAL TRIALS AS TOPIC; DISEASE MANAGEMENT; HUMANS;

EID: 84923219855     PISSN: 15420124     EISSN: 19375913     Source Type: Journal    
DOI: 10.1016/j.jtos.2014.05.005     Document Type: Review

References (69)

1. American Academy of Ophthalmology. Preferred Practice Pattern: Blepharitis. October 2011 revision. Available at: http://one.aao.org/CE/PracticeGuidelines/PPP-Content.aspx?cid500cd9ca-173c-4c31-b6ea-a258e3549474. Accessed June 6, 2013
2. Lemp MA, Nichols KK. Blepharitis in the United States 2009: a survey-based perspective on prevalence and treatment. Ocul Surf 2009;7(2 suppl):S1-14
3. Lindsley K, Matsumura S, Hatef E, Akpek EK. Interventions for chronic blepharitis (Review). Cochrane Database Syst Rev 2012;16:5. CD005556
4. Viso E, Rodríguez-Ares MT, Abelenda D, et al. Prevalence of asymptomatic and symptomatic meibomian gland dysfunction in the general population of Spain. Invest Ophthalmol Vis Sci 2012;53:2601-6
5. Bernardes TF, Bonfioli AA. Blepharitis. Semin Ophthalmol 2010;25: 79-83
6. Hom MM, Martinson JR, Knapp LL, Paugh JR. Prevalence of Meibo-mian gland dysfunction. Optom Vis Sci 1990;67:710-20
7. Patel KG, Raju VK. Ocular demodicosis. W V Med J 2013;109:16-8
8. O'Brien TP. The role of bacteria in blepharitis. Ocul Surf 2009;7(2 suppl):S21-2
9. Filho PAN, Hazarbassanov RM, Grisolia ABD, et al. The efficacy of oral ivermectin for the treatment of chronic blepharitis in patients tested positive for Demodex spp. Br J Ophthalmol 2011;95:893-5
10. Zhao YE, Wu LP, Hu L, Xu JR. Association of blepharitis with Demo-dex: a meta-analysis. Ophthalmic Epidemiol 2012;19:95-102
11. Malerbi FK, Martins LC, Saldiva PH, Braga AL. Ambient levels of air pollution induce clinical worsening of blepharitis. Environ Res 2012;112:199-203
12. Tesón M, González-Garcia MJ, López-Miguel A, et al. Influence of a controlled environment simulating an in-flight airplane cabin on dry eye disease. Invest Ophthalmol Vis Sci 2013;54:2093-9
13. Geerling G, Tauber J, Baudouin C, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthal-mol Vis Sci 2011;52:2050-64
14. Scaffidi RC, Korb DR. Comparison of the efficacy of two lipid emulsion eye drops in increasing tear film lipid layer thickness. Eye Contact Lens 2007;33:38-44
15. Sindt CW, Foulks GN. Efficacy of an artificial tear emulsion in patients with dry eye associated with meibomian gland dysfunction. Clin Oph-thalmol 2013;7:1713-22
16. Kheirkhah A, Casas V, Li W, et al. Corneal manifestations of ocular demodex infestation. Am J Ophthalmol 2007;143:743-9
17. Holzchuh FG, Hida RY, Moscovici BK, et al. Clinical treatment of ocular Demodex folliculorum by systemic ivermectin. Am J Ophthalmol 2011;151:1030-4
18. Freidlin J, Acharya N, Lietman TM, et al. Spectrum of eye disease caused by methicillin-resistant Staphylococcus aureus. Am J Ophthal-mol 2007;144:313-5
19. Haas W, Pillar CM, Torres M, et al. Monitoring antibiotic resistance in ocular microorganisms: results from the Antibiotic Resistance Monitoring in Ocular micRorganisms (ARMOR) 2009 surveillance study. Am J Ophthalmol 2011;152:567-74
20. Miller D, Chang JS, Flynn HW, Alfonso EC. Comparative in vitro susceptibility of besifloxacin and seven comparators against ciprofloxa-cin-and methicillin-susceptible/nonsusceptible staphylococci. J Ocul Pharmacol Ther 2013;29:339-44
21. Asbell PA, Colby KA, Deng S, et al. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates. Am J Ophthalmol 2008;145:951-8
22. Pleyer U, Ursell PG, Rama P. Intraocular pressure effects of common topical steroids for post-cataract inflammation: are they the same? Oph-thalmol Ther 2013. http://dx.doi.org/10.1007/s40123-013-0020-5
23. Perry HD, Doshi-Carnevale S, Donnenfeld ED, et al. Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction. Cornea 2006;25:171-5
24. Prabhasawat P, Tesavibul N, Mahawong W. A randomized double-masked study of 0.05% cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunction. Cornea 2012;31: 1386-93
25. Rubin M, Rao SN. Efficacy of topical cyclosporine 0.05% in the treatment of posterior blepharitis. J Ocul Pharmacol Ther 2006;22: 47-53
26. Maskin SL. Intraductal meibomian gland probing relieves symptoms of obstructive meibomian gland dysfunction. Cornea 2010;29:1145-52
27. Macsai MS. The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis). Trans Am Ophthalmol Soc 2008;106:336-56
28. Barabino S, Rolando M, Camicione P, et al. Systemic linoleic acid therapy in dry eye syndrome with an inflammatory component. Cornea 2003;22:97-101
29. Creuzot-Garcher C, Baudouin C, Labetoulle M, et al. Efficacy assessment of Nutrilarm® a per os omega-3 and omega-6 polyunsaturated essential fatty acid dietary formulation versus placebo in patients with bilateral treated moderate dry eye syndrome. J Fr Ophthamol 2011;34: 448-55
30. Kokke KH, Morris JA, Lawrenson JG. Oral omega-6 essential fatty acid treatment in contact lens associated dry eye. Cont Lens Anterior Eye 2008;31:141-6
31. Sheppard Jr JD, Singh R, McClellan AJ, et al. Long-term supplementation with n-6 and n-3 PUFAs improves moderate-to-severe keratoconjunctivitis sicca: a randomized double-blind clinical trial. Cornea 2013;32:1297-304
32. Brignole-Baudouin F, Baudouin C, Aragona P, et al. A multicenter, double-masked, randomized, controlled trial assessing the effect of oral supplementation of omega-3 and omega-6 fatty acids on a conjunctival inflammatory marker in dry eye patients. Acta Ophthalmol 2011;89:e591-7
33. 1 tear content in Sjögren's syndrome patients. Invest Ophthalmol Vis Sci 2005;46:4474-9
34. Pinna A, Piccinini P, Carta F. Effect of oral linoleic and gamma-linolenic acid on meibomian gland dysfunction. Cornea 2007;26:260-4
35. Jackson WB. Blepharitis: current strategies for diagnosis and management. Can J Ophthalmol 2008;43:170-9
36. Fadlallah A, Rami HE, Fahd D, et al. Azithromycin 1.5% ophthalmic solution: efficacy and treatment modalities in chronic blepharitis. Arq Bras Oftalmol 2012;75:178-82
37. Torkildsen GL, Cockrum P, Meier E, et al. Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0. 3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivi-tis. Curr Med Res Opin 2011;27:171-8
38. Opitz DL, Tyler KF. Efficacy of azithromycin 1% ophthalmic solution for treatment of ocular surface disease from posterior blepharitis. Clin Exp Optom 2011;94:200-6
39. Foulks GN, Borchman D, Yappert M, et al. Topical azithromycin therapy of meibomian gland dysfunction: clinical response and lipid alterations. Cornea 2010;29:781-8
40. Haque RM, Torkildsen GL, Brubaker K, et al. Multicenter open-label study evaluating the efficacy of azithromycin ophthalmic solution 1% on the signs and symptoms of subjects with blepharitis. Cornea 2010;29:871-7
41. Luchs J. Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis. Adv Ther 2008;25:858-70
42. Akpek EK, Vittitow J, Verhoeven RS, et al. Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation. J Ocul Pharmacol Ther 2009;25:433-9
43. Wang MG, Zhang YY, Zhu DM, et al. Postantibiotic effects of eleven antimicrobials on five bacteria. Acta Pharmacol Sin 2001;22:804-8
44. Yactayo-Miranda Y, Ta CN, He L, et al. A prospective study determining the efficacy of topical 0.5% levofloxacin on bacterial flora of patients with chronic blepharoconjunctivitis. Graefes Arch Clin Exp Ophthalmol 2009;247:993-8
45. John G. A comparative study in the clinical and microbial efficacy of topical besifloxacin ophthalmic suspension 0.6% with erythromycin ophthalmic ointment 0.5% for the management of acute blepharitis (poster). Presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL, May 6-9, 2012
46. Comstock TL, Holland EJ. Loteprednol and tobramycin in combination: a review of their impact on current treatment regimens. Expert Opin Pharmacother 2010;11:843-52
47. Cochereau I, Meddeb-Ouertani A, Khairallah M, et al. 3-day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobra-mycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children. Br J Ophthalmol 2007;91:465-9
48. Protzko E, Bowman L, Abelson M, Shapiro A. AzaSite Clinical Study Group. Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis. Invest Ophthalmol Vis Sci 2007;48:3425-9
49. Clark AF. Basic sciences in clinical glaucoma: steroids, ocular hypertension, and glaucoma. J Glaucoma 1995;4:354-69
50. Chen M, Gong L, Sun X, et al. A multicenter, randomized, parallel-group, clinical trial comparing the safety and efficacy of loteprednol eta-bonate 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0. 3% in the treatment of Chinese patients with blepharokeratoconjuncti-vitis. Curr Med Res Opin 2012;28:385-94
51. White EM, Macy JI, Bateman KM, Comstock TL. Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexa-methasone 0.1%/tobramycin 0.3% in the treatment of blepharokerato-conjunctivitis. Curr Med Res Opin 2008;24:287-96
52. Rhee SS, Mah FS. Comparison of tobramycin 0.3%/dexamethasone 0. 1% and tobramycin 0.3%/loteprednol 0.5% in the management of ble-pharo-keratoconjunctivitis. Adv Ther 2007;24:60-7
53. Zylet [package insert]. Tampa, FL: Bausch & Lomb Inc; 2013
54. Tobradex [package insert]. Fort Worth, TX: Alcon Laboratories; 2009
55. Bartlett JD, Holland EJ, Usner DW, et al. Tolerability of loteprednol/tobramycin versus dexamethasone/tobramycin in healthy volunteers: results of a 4-week, randomized, double-masked, parallel-group study. Curr Med Res Opin 2008;24:2219-27
56. Belfort Jr R, Gabriel L, Martins Bispo PJ, et al. Safety and efficacy of moxifloxacin-dexamethasone eyedrops as treatment for bacterial ocular infection associated with bacterial blepharitis. Adv Ther 2012;29:416-26
57. Dell SJ, Shulman DG, Lowry GM, Howes J. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group. Am J Ophthalmol 1997;123:791-7
58. Stewart R, Horwitz B, Howes J, et al. Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-operative Inflammation Study Group 1. J Cataract Refract Surg 1998;24:1480-9
59. Comstock TL, Paterno MR, Singh A, et al. Safety and efficacy of lote-prednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery. Clin Ophthalmol 2011;5:177-86
60. Holland EJ, Bartlett JD, Paterno MR, et al. Effects of loteprednol/tobra-mycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers. Cornea 2008;27:50-5
61. Bodor N, Loftsson T, Wu WM. Metabolism, distribution, and trans-dermal permeation of a soft corticosteroid, loteprednol etabonate. Pharm Res 1992;9:1275-8
62. Bodor N, Buchwald P. Soft drug design: general principles and recent applications. Med Res Rev 2000;20:58-101
63. Comstock TL, Decory HH. Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate. Int J Inflam 2012;2012: 789623. http://dx.doi.org/10.1155/2012/789623
64. Igami TZ, Holzchuh R, Osaki TH, et al. Oral azithromycin for treatment of posterior blepharitis. Cornea 2011;30:1145-9
65. Yoo SE, Lee DC, Chang MH. The effect of low-dose doxycycline therapy in chronic meibomian gland dysfunction. Korean J Ophthalmol 2005;19:258-63
66. Foulks GN, Borchman D, Yappert M, Kakar S. Topical azithromycin and oral doxycycline therapy of meibomian gland dysfunction: a comparative clinical and spectroscopic pilot study. Cornea 2013;32: 44-53
67. Lee H, Min K, Kim EK, Kim TI. Minocycline controls clinical outcomes and inflammatory cytokines in moderate and severe meibomian gland dysfunction. Am J Ophthalmol 2012;154:949-57
68. Vargas JM, Aronowicz J, Shine WE, et al. Short-term treatment of chronic blepharitis with oral minocycline [abstract]. Annual Meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL, USA; May 4-8, 2003
69. Gumus K, Cavanagh DH. The role of inflammation and antiinflamma-tion therapies in keratoconjunctivitis sicca. Clin Ophthalmol 2009;3: 57-67